Breaking Down Oral And Transdermal Peptide Delivery

About this video

In this protocol discussion Seeds expresses strong scepticism about oral, sublingual, and transdermal peptide delivery. He claims sublingual bioavailability is very low, that validated pharmacokinetic data are lacking, and that no universally accepted liposomal platform currently proves equivalence to injection. He contrasts that uncertainty with injected delivery, which he presents as far more reliable, and notes that even well-studied oral products in related drug classes required complex formulation work and much larger amounts of material, raising cost. His conclusion is that advanced oral formulations may be in development, but Seeds argues clinicians should not treat current products as proven substitutes.

Key takeaways

• Demand pharmacokinetic data before accepting oral or sublingual equivalence claims, Seeds urges
• Low absorption has cost consequences because more material is needed to compensate
• Seeds treats injection as the current reference standard for delivery reliability
• A plausible formulation idea is not the same as a validated delivery platform

Episode details: published May 25, 2026 · 369 views · 2:57 long. Summary written by Self Growth Videos from the episode itself. The peptide and cellular-medicine concepts described are Dr. William Seeds’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: the SSRP Institute sells clinician certification in peptide therapy.

← Previous: Debunking Misleading Studies #peptides #health · Next: The B Vitamin You’re Probably Overdosing On #peptides #health →

All Dr. William Seeds videos · Dr. William Seeds profile · SSRP Institute (official site)